Publication

Video

Supplements and Featured Publications

My Treatment Approach: Locally Advanced Lung Cancer
Volume1
Issue 1

Dr. Costin on Initial Considerations in Early-Stage Lung Cancer

Dan Costin, MD, discusses initial considerations in early-stage lung cancer.

Dan Costin, MD, co-medical director, White Plains Hospital Center for Cancer Care, director, Cancer and Blood Specialists of New York, discusses initial considerations in early-stage lung cancer.

Patients with early-stage lung cancer typically require a multidisciplinary approach to treatment, says Costin. For example, thoracic surgeons, in addition to medical oncologists, will often be involved in initial treatment decisions.

In the early-stage setting, tissue diagnosis and appropriate staging are needed, says Costin. The majority of patients will undergo a CT-guided biopsy or a navigational bronchoscopy to determine tissue diagnosis. For staging, patients typically undergo a PET scan.

For a patient with a confirmed diagnosis of early-stage lung cancer, initial treatment selection is based on factors such as patient comorbidities, surgical eligibility, and results of molecular testing, concludes Costin.

Related Videos
Steven H. Lin, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.